• €800K Grant supports Large B-cell Lymphoma Project

News & Views

€800K Grant supports Large B-cell Lymphoma Project

Jul 15 2022

Therapeutics developer Lead Pharmaceutical (Oss, Netherlands) and French medicinal chemistry and custom synthesis company Oxeltis, have been awarded an €800K ($842K) grant from EUREKA Eurostars for a three year project aimed at developing a first-in-class small molecule therapy for diffuse large B-cell lymphoma (DLBCL). This aggressive, fast-growing blood cancer that develops from B-cells in the lymphatic system, affects approximately 115,000 people per year worldwide, of which 50,000 were said to be in Europe and the US

The current first-line treatment for DLBCL, a regimen combining an antibody therapy with four chemotherapy drugs known as R-CHOP, does not cure 30-50% of DLBCL patients, who eventually relapse.

Arthur Oubrie, CSO of Lead Pharma said: “We are delighted that our approach to combat DLBCL has been awarded a Eurostars grant. We look forward to joining forces with Oxeltis, who will bring extra power in organic and medicinal chemistry to the joint project team.”

Stephane Salamone、化学Montpelli主管er-based Oxeltis, said: “We are pleased to contribute to Lead Pharma’s innovation in drug discovery, the EPIGENEXT project perfectly matches Oxeltis’ capacity to be a medicinal chemistry partner and is aligned with the company’s strategy to invest in long-term partnerships.

Eurostars is a European program that supports innovative SMEs and project partners (small and medium-sized companies, universities, research organisations and other types of organisations) by funding international collaborative R&D and innovation projects. The Program is run by EUREKA, an intergovernmental network which involves 37 countries.

更多的信息online